key: cord-0750279-1y0mz89o authors: Thammathiwat, Theerachai; Tungsanga, Somkanya; Tiankanon, Kanitha; Torvorapanit, Pattama; Chumpangern, Worawat; Udomkarnjananun, Suwasin; Avihingsanon, Yingyos; Sriprasart, Thitiwat; Srisawat, Nattachai; Jutivorakool, Kamonwan; Paitoonpong, Leilani; Putcharoen, Opass; Townamchai, Natavudh title: A case of successful treatment of severe COVID‐19 pneumonia with favipiravir and tocilizumab in post–kidney transplant recipient date: 2020-07-10 journal: Transpl Infect Dis DOI: 10.1111/tid.13388 sha: 1e1a2f3225ba268752df741d14eb2ac0e0684e86 doc_id: 750279 cord_uid: 1y0mz89o We report a case of COVID‐19 in kidney transplant patient in Thailand. A 58‐year‐old 2 years post–kidney transplant recipient, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil (MMF), and prednisolone, presented with acute diarrhea which followed by fever on day 12. Symptoms of pneumonia together with lymphopenia from complete blood count were developed on day 7 after onset of fever with the x‐ray finding of bilateral multifocal patchy infiltration. COVID‐19 infection has been confirmed by reverse real‐time polymerase chain reaction (PCR) in nasal swab as well as found in stool. Darunavir together with ritonavir, hydroxychloroquine, azithromycin, and favipiravir was initiated on the first day of admission at primary hospital. Patient has been transferred to our hospital on day 2 of admission in which tacrolimus together with MMF was discontinued. High‐flow nasal cannula oxygen therapy was required on days 4‐5 of hospitalization. Tocilizumab was administered after rising of serum IL‐6 level. Symptoms of pneumonia were improved in which no oxygen treatment required from day 10 of hospitalization. Drug interaction between tacrolimus and anti‐viral treatment leads to severely high level of tacrolimus which caused reversible acute kidney injury (AKI) after supportive treatment. transplant recipient. [4] [5] [6] Immunosuppressive drug may alter clinical presentation and severity of COVID-19. 7 Herein, we reported favorable outcome of severe COVID-19 pneumonia in kidney transplant recipient. A 58-year-old man, taxi driver, who underwent first kidney transplantation from his wife 2 years ago with stable serum creatinine around 1.4 mg/dL, was referred from primary hospital with symptom of acute fever, nausea, and watery diarrhea followed by progressive dyspnea within 2 days. He also has underlying of hypertension, dys- On March 13, 2020, he developed his first clinical presentation that was episodic watery diarrhea for 12 days and then followed by fever, myalgia, and dry cough. On day 6 of fever, he had shortness of breath which leads him to primary hospital the next day. Physical examination revealed body temperature of 39.2 degrees Celsius, blood pressure 118/65 mm Hg, pulse rate 92 beats per minute, respiratory rate 24 times per minutes, and oxygen saturation at room air of 94%. Respiratory examination revealed fine crepitation in both lung fields. Since taxi driver has been considered as high-risk occupation, he underwent nasal swab for SARS-CoV-2 by real-time reverse real-time PCR which revealed positive for COVID-19. Stool testing for SARS-CoV-2 by real-time reverse real-time PCR also revealed positive. Chest radiography was reported bilateral multifocal patchy infiltration ( Figure 1 ). He has been diagnosed as having COVID-19 pneumonia. Azithromycin together with hydroxychloroquine, darunavir, ritonavir, and favipiravir has been initiated ( Figure 2 ). Tacrolimus dosage was decreased for 50%, and MMF was discontinued. Prednisolone has been continued with dose of 2.5 mg/d and prompted increase if there was sign and symptom of adrenal insufficiency. Ceftriaxone has also been initiated to prophylaxis for concomitant bacterial infection. On day 2 of admission, he required oxygen therapy to maintain adequate oxygenation. He has been transferred to our hospital which is an organ transplant center. The initial laboratory results showed lymphopenia of 452 cells/µL, rising of Cr from 1.4 at baseline to 2.2 mg/dL, serum Na of 128 mEq/L, and IL-6 level of 17.1 pg/mL (reference level < 7 pg/mL). Tacrolimus trough level revealed 28.9 ng/ mL which leads to discontinuation of tacrolimus, darunavir, ritonavir, and azithromycin. On days 4-5 of admission (day 11-12 of fever), lymphocyte count was decreased to 250 cells/µL, PaO 2 /FiO 2 ratio was lowered to 226, and the chest radiography revealed increased bilateral infiltration which required high-flow nasal cannula oxygen therapy. The intravenous immunoglobulin (IVIg) 2 g/kg/d was administered for 2 consecutive days. He also underwent polymyxin B hemoperfusion which was indicated by increased level of endotoxin tested by EEA™. On day 6, the IL-6 level increased to 569 pg/mL, and single dose of 8 mg/kg of tocilizumab was administered. The clinical of patient was improved which no longer oxygen therapy required on day 4 following initiation of tocilizumab. The infiltration was significantly decreased on chest radiography. However, despite early discontinuation of tacrolimus together with darunavir F I G U R E 1 Chest radiography of the patient and ritonavir, the trough level of tacrolimus was peaked on day 4 of admission which was 49.4 ng/mL. Tacrolimus has been withdrawn for 10 days until the trough level was lowered to therapeutic level which was the same period as his serum Cr returned to baseline. After symptoms were improved, the MMF was reintroduced after lymphopenia was recovered and COVID-19 was undetected. The recent data hypothesized that COVID-19 leads to activation immune system, including T cells, which causes severe lung tissue injury with evidence of CD4 T cells in post-mortem biopsy of ARDS patient and subsequently shows lymphocytopenia in severe disease. 8 Coronavirus disease (COVID-2019) situation reports Clinical characteristics of coronavirus disease 2019 in China The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis. medRxiv Identification of kidney transplant recipients with coronavirus disease 2019 COVID-19 infection in kidney transplant recipients COVID-19 in post-transplantation patients-report of two cases Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis The occurrence of diarrhea in COVID-19 patients Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection Experimental treatment with favipiravir for COVID-19: an open-label control study Favipiravir versus Arbidol for COVID-19: a randomized clinical trial Interleukin-6 as a potential biomarker of COVID-19 progression Tocilizumab treatment in COVID-19: a single center experience Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient